Don A. Kennard

  • Citations Per Year
Learn More
Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of subcutaneously delivered fluids and drugs. This report summarizes rHuPH20 immunogenicity findings from clinical trials where rHuPH20 was co-administered with SC human immunoglobulin, trastuzumab, rituximab, or insulin. Plasma samples were obtained from evaluable subjects(More)
1 Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, California 92121, USA. 2 Baxter Bioscience, Deerfield, Illinois, USA. 3 Baxter Bioscience, Vienna, Austria. 4 Baxter Healthcare Corporation, Deerfield, Illinois, USA. 5 To whom correspondence should be addressed. (e-mail: srosengren@halozyme.com) The AAPS Journal, Vol. 17, No. 6, November(More)
  • 1